ISPOR Europe 2026: HEOR and Market Access | PPD

ISPOR 2026 corporate partner

Evidence designed for access and built for the decisions ahead

Meet us at ISPOR Europe 2026

Meet our experts at ISPOR Europe 2026 to explore how integrated evidence strategies can help you prepare for the decisions that shape successful market access. From evolving HTA and payer requirements to the growing role of real-world evidence and AI, discover how designing the right evidence earlier can help demonstrate value across markets, navigate changing evidence expectations, and ultimately accelerate patient access.

View our event schedule

designing-for-access-webinar

designing-for-access-webinar

Designing for access: Early integrated evidence generation planning

Learn how early integrated evidence generation planning can align HTA, payer and regulatory needs to support confident access decisions.

Navigate the EU HTA regulation

2025 conference poster portfolio

RWE studies – diverse data designs

Registries and RWE

Our solutions

EU HTA regulation

Navigating you through the complexities of the EU HTA Regulation and overcoming the challenges to successful market access for your asset.

Patient-centered research

Patient-centered research solutions that integrate the patient voice to strengthen value narratives and submissions, and improve uptake of your asset.

Real-world data & evidence

Real-world data and evidence solutions that fast track approval and secure market access for your asset.

Event schedule

Educational symposium

Monday, 9 November | 12:15pm – 1:15pm

TBC

Speakers: TBC

Workshop

Monday, 9 November | 4:45pm – 5:15pm

Mixture Cure Models: Do They Create More Issues Than They are Trying to Solve?

Speakers: Irina Proskorovsky

Tuesday, 10 November | 4:45pm – 5:15pm

Accounting for Preference Heterogeneity in Stated Choice Data: From Good-Practice Methods to Decision-Relevant Interpretation

Speakers: Sebastian Heidenreich

Issue panels

Tuesday, 10 November | 1:45pm – 2:45pm

Train the Economist or Hire the Engineer? The Future of Expertise in AI-Native HEOR

Speakers: Jaime Caro

Wednesday, 11 November | 8:00am – 9:00am

How Should Evidence be Assessed in Rare Diseases?

Speakers: Jaime Caro

Spotlight

Monday, 9 November | 10:30am – 11:30am

Humans at the Helm: Navigating Increasing AI Autonomy in HEOR and HTA

Speakers: Jaime Caro

Related resources

designing-for-access-webinar

designing-for-access-webinar

Designing for access: Early integrated evidence generation planning

Learn how early integrated evidence generation planning can align HTA, payer and regulatory needs to support confident access decisions.

Team discussing analytics as discussed in the

Team discussing analytics as discussed in the

Transportability in Health Technology Assessment

Learn why transportability in health technology assessment is essential for credible reimbursement decisions and explore emerging methods shaping HTA.

AI HEOR evidence symposium webinar

AI HEOR evidence symposium webinar

Transforming HEOR with AI and Real-World Data

Explore how AI and real-world data can strengthen HEOR, evidence generation and health economic modeling across the therapy lifecycle.

Title screen of the presentation,

Title screen of the presentation,

Strategic Insights From 5 Years of the EU HTAR: Unleashing the Ambition for Orphan Products and Vaccines

Explore guidance from 5 years of EU HTAR experience, including Smart PICO, early readiness, and evidence strategies for orphan drugs and vaccines.

Beyond weight loss: Obesity trial design for real-world patient and payer impact

Generate obesity evidence that supports regulatory approval, payer access and long-term patient impact. Learn strategies for designing trials that deliver meaningful clinical, economic and real-world value.

Precision-therapy-market-access-webinar

Precision-therapy-market-access-webinar

From biomarker to market: Optimizing access for precision therapies

Learn practical strategies to accelerate market access for precision therapies using real-world evidence and biomarker insights.